ºñÀΰ¾Ï ȯÀÚÀÇ ¿¹ÈÄ¿¡¼ 2-[18F] Fluoro-2-Deoxy-D-Glucose PET ¿µ»ó¿¡¼ °è»êµÇ´Â Standardized Uptake ValueÀÇ ÀÇÀÇ
Prediction of Prognosis to Concurrent Chemo-Radiotherapy by Standardized Uptake Value of 2-[18F] Fluoro-2-Deoxy-D-Glucose for Nasopharyngeal Carcinomas
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌ»ó¿í/Lee SW
ÀÓ±âõ/³²¼ø¿/±èÀç½Â/ÃÖÀº°æ/¾È½Âµµ/½Å¼º¼ö/·ùÁø¼÷/±è»óÀ±/À̺ÀÀç/ÃÖ½ÂÈ£/±è¼º¹è/¹®´ëÇõ/±èÁ¾ÈÆ
KMID : 0859320050230010009
Abstract
¸ñ Àû: ¿ø°ÝÀå±âÀÇ ÀüÀÌ°¡ ¾ø´Â ºñÀΰ¾Ï¿¡¼ µ¿½ÃÇ×¾ÏÈÇйæ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº ȯÀÚ¿¡¼ Áø´Ü ´ç½Ã ½ÃÇàÇÑ ¾çÀüÀÚ´ÜÃþÃÔ¿µÀÇ fluorodeoxyglucose (FDG) ¼·ÃëÁ¤µµ°¡ ¿¹ÈÄ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: º»¿ø¿¡¼ ¿ø°ÝÀå±âÀÇ ÀüÀÌ°¡ ¾ø´Â ºñÀΰ¾ÏÀ¸·Î Áø´Ü ¹Þ°í Áø´Ü ´ç½Ã [18F]FDG-PETÀ» ½ÃÇàÇÑ È¯ÀÚ´Â ÃÑ 41¸íÀ̾ú´Ù. PET °Ë»ç´Â ¸ðµÎ Ç׾Ϲæ»ç¼±Ä¡·á Àü¿¡ ½ÃÇàµÇ¾ú´Ù. FDG ¼·Ãë Á¤µµ¸¦ ¾Ë¾Æº¸±â À§Çؼ Á¾¾ç ³»¿¡¼ ÃøÁ¤µÈ ÃÖ´ë standardized uptake value (SUV)¸¦ ÃøÁ¤ÇÏ¿´´Ù.
°á °ú: Ç×¾ÏÈÇйæ»ç¼±Ä¡·á ÈÄ ¸ðµç ȯÀÚ´Â ¿ÏÀü¹ÝÀÀÀ» º¸¿´´Ù. Àüü 41¸í Áß¿¡¼ 10¸íÀÌ Àç¹ßÇÏ¿´´Âµ¥ Àç¹ßÇÏÁö ¾ÊÀº ȯÀÚÀÇ SUVmax Áß¾Ó°ªÀº 6.48 (range: 2.31¢¦26.07)À̾ú°í Àç¹ßÇÑ È¯ÀÚÀÇ Áß¾Ó SUVmax´Â 8.55 (2.49¢¦14.81)À̾ú´Ù. ¾ç ±º °£ÀÇ SUVÀÇ Â÷ÀÌ´Â p°ªÀÌ 0.0505·Î Åë°èÀû Â÷ÀÌ°¡ °üÂûµÇÁö ¾Ê¾Ò´Ù. SUVmax¸¦ Áß¾Ó°ªÀ» ±âÁØÀ¸·Î ³ª´©¾î º¸¾ÒÀ» ¶§ SUVmax°¡ ³ôÀº ȯÀÚÀÇ 3³â »ýÁ¸À²ÀÌ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ÀúÁ¶ÇÏ¿´´Ù(51% ¥í 91%, p=0.0070).
°á ·Ð: ¿ø°ÝÀüÀÌ°¡ ¾ø´Â ºñÀΰ¾Ï¿¡¼ Ç×¾ÏÈÇйæ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº ȯÀÚ¿¡¼ Áø´Ü ´ç½Ã ½ÃÇàÇÑ FDG ¼·Ãë Á¤µµ´Â ¿¹Èĸ¦ ¿¹ÃøÇϴµ¥ À¯¿ëÇÒ °ÍÀ¸·Î »ý°¢µÇ¾ú´Ù. µû¶ó¼ Áø´Ü ´ç½Ã ½ÃÇàÇÑ FDG-PET¿¡¼ SUV°¡ ³ôÀº °æ¿ì(8 ÀÌ»ó)¿¡´Â Á»´õ Àû±ØÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢ÇÏ¿´´Ù.
Purpose: To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict disease-free survival (DFS) after concurrent chemo-radiotherapy (CCRT) in patients with non-disseminated nasopharyngeal carcinoma (NPC).
Materials and Methods: We studied 41 patients with non-disseminated NPC scheduled to undergo platinum- based CCRT were eligible for this study. Patients were studied by FDG-PET prior to the CCRT. FDG uptake of tumors were measured with the maximal standardized uptake value (SUV).
Results: Complete response rate was 100%. In ten patients who presented with any component of treatment failure, the median SUVmax was 8.55 (range: 2.49¢¦14.81) in any component of failure and the median SUVmax was 6.48 (range: 2.31¢¦26.07) in the remaining patients without any such failure. Patients having tumors with high FDG uptake had a significantly lower 3-year DFS (51% ¥í 91%, P=0.0070) compared with patients having low uptake tumors.
Conclusion: FDG uptake, as measured by the SUV, has potential value in predicting DFS in NPC treated by CCRT. High FDG uptake may be a useful parameter for identifying patients requiring more aggressive treatment approaches.
Å°¿öµå
Nasopharyngeal carcinoma;FDG-PET;CCRT;ºñÀΰ¾Ï;[18F]FDG-PET;µ¿½ÃÇ×¾ÏÈÇйæ»ç¼±Ä¡·á
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸